Chief of Myeloma Service Member, Myeloma, Cellular Therapy and Adult BMT Services Memorial Sloan Kettering Cancer Center, New York, NY Professor, Weill Cornell Medical College, Cornell University
Dr. Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. He joined the Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences in Little Rock, AR in 2010 as the Director of Developmental Therapeutics. He was recruited to the Levine Cancer Institute/Atrium Health in 2013 as the inaugural Division Chief of Plasma Cell Disorders and Director of Clinical Research for Hematologic Malignancies where he built an internationally renowned myeloma program. He joined Memorial Sloan Kettering Cancer Center in 2021 as the Chief of Myeloma Service and holds a faculty position as Professor of Clinical Medicine at Weill Cornell Medical College, Cornell University. Dr. Usmani is board-certified in internal medicine, medical oncology, and hematology. He is a Fellow of the American College of Physicians, Fellow of the Royal College of Physicians (UK), and Fellow of the American Society of Clinical Oncology. He holds membership and leadership roles on national/international committees, including the International Myeloma Working Group (Scientific Advisory Board Member), the ALLIANCE Myeloma NCTN Committee (Chair), the American Society of Hematology (ASH), the American Society of Clinical Oncology, International Myeloma Society (Board Member), the American Society of Transplant & Cellular Therapy, and the National Cancer
Institute Myeloma Steering Committee. Dr. Usmani has served as the Vice-Chair of the SWOG Myeloma Committee and has served as chair for the ASH Scientific Committee on Plasma Cell Neoplasia, and the ASCO Scientific Committee on Lymphoma and Plasma Cell Disorders. He has received several international awards recognizing his clinical and translational research contributions to the field, including the Celgene Young Investigator Award for Clinical Research, COMY Award for
Excellence in Myeloma Research, LLS Scholar in Clinical Research, the International Myeloma Society Bart Barlogie Award for Clinical and Translational Research, the LLS CDP Achievement Award, and the Giants in Cancer Care Award. He has led the clinical development of several novel therapies, including anti-CD38 monoclonal antibodies, bispecific antibodies and CART cell therapies resulting in regulatory approvals in multiple myeloma. Dr. Usmani has authored/co-authored more than 360 peer-reviewed research manuscripts (NEJM, Lancet, Nature Medicine, JCO, Cancer Cell, Blood, Leukemia, etc.). Active in clinical and translational research, Dr. Usmani has research interests focused on plasma cell disorders—in particular, high-risk multiple myeloma.
